# A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects

> **NCT05103878** · PHASE1 · COMPLETED · sponsor: **Bacainn Therapeutics, Inc.** · enrollment: 50 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** BT051 100mg
- **DRUG:** BT051 300mg
- **DRUG:** BT051 700mg
- **DRUG:** BT051 1500mg
- **DRUG:** BT051 3500mg
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT05103878
- **Lead sponsor:** Bacainn Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-24
- **Primary completion:** 2020-11-13
- **Final completion:** 2020-11-13
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2022-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05103878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05103878, "A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05103878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*